Clinical development of new drug–radiotherapy combinations
Stephen R. Wedge(Newcastle University), Lucinda Billingham(University Hospitals Birmingham NHS Foundation Trust), Sean Buckland(Pfizer (United Kingdom)), Tom Haswell(University of Oxford), Andrew S. Kennedy(Sarah Cannon), Roberta Ferraldeschi(Royal Marsden NHS Foundation Trust), Richard Adams(Velindre Cancer Centre), Thorsten Melcher(University of Manchester), M. Hawkins(University College Hospital), Ricky A. Sharma(Siemens Healthcare (United States)), John Staffurth(Velindre NHS Trust), Lars Damstrup(Merck KGaA, Darmstadt (Germany)), Helen Bulbeck(Entrust), Mark Saunders(Manchester Academic Health Science Centre), Aaron Cranston(AstraZeneca (United Kingdom)), Julie Stock(University of Oxford), Ö. Ataman(Pfizer (United Kingdom)), Ruth Plummer(National Health Service), David Sebag‐Montefiore(University of Leeds), Emma Hall(Institute of Cancer Research), Glen Clack(University of Sheffield), Ian J. Stratford(University of Manchester), Anthony J. Chalmers(Beatson West of Scotland Cancer Centre), Sarah Brown(University of Leeds), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Tim Illidge(Manchester Academic Health Science Centre), Martin Förster, Richard D. Baird(Cancer Research UK), John R. Pollard(Vertex Pharmaceuticals (United Kingdom)), James P.B. O’Connor(Cancer Research UK), Stephen Kelly(Barts Health NHS Trust), Fiona McDonald(Royal Marsden Hospital), Hazel Jones(Sarah Cannon), Axel‐R. Hanauske(TUM Klinikum), Russell M. Hagan(Institute of Cancer Research), Melanie C. Smitt(Velindre Cancer Centre), Robert Clay(Digital Catapult (United Kingdom)), Julian M.C. Golec(Vertex Pharmaceuticals (United Kingdom))
Cited by 317
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k